2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

201. Granulocytes, Monocytes, and Macrophages: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Bioinformatics, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Diseases, Bone Marrow Failure Syndromes, Immunology, Autoimmune Disorders, Immunodeficiency, Neutropenia, White Blood Cell Disorders, Infectious Diseases, Viral, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, B Cell Lymphoma, T Cell Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Pediatric, Pregnant
PAPER

4723 Beyond idiopathic: A progesterone-BCL2A1 survival axis defines a reproductive endocrine subtype of chronic neutropenia

Mark David Orland, MD, PhD, Aashray Mandala2, Luca Guarnera, MD3, Carlos Bravo-Perez, MD4, Nandini Rajaram Siva, MD5, Atsushi Marumo, MD6, Arda Durmaz, PhD7, Carmelo Gurnari, MD,PhD8, Valeria Visconte, PhD9, Jaroslaw P. Maciejewski, MD, PhD, FACP10
1 Case Western Reserve University School of Medicine, Cleveland, Ohio, United States, Cleveland Clinic, Cleveland, Ohio, United States
2 Cleveland Clinic, Cleveland, Ohio, United States
3 Cleveland Clinic, Cleveland, Ohio, United States, Tor Vergata University, Rome, Italy
4 Cleveland Clinic, Cleveland, Ohio, United States
5 Case Western Reserve University School of Medicine, Cleveland, Ohio, United States
6 Cleveland Clinic, Cleveland, Ohio, United States
7 Cleveland Clinic, Cleveland, Ohio, United States
8 Cleveland Clinic, Cleveland, Ohio, United States, Tor Vergata University, Rome, Italy
9 Cleveland Clinic, Cleveland, Ohio, United States
10 Cleveland Clinic, Cleveland, Ohio, United States

Background: An otherwise healthy woman presented with chronic cyclic neutropenia characterized by recurrent neutrophil nadirs during estrogen-dominant phases of the menstrual cycle and spontaneous recovery during progesterone-dominant phases. Her neutropenia improved with exogenous progestin therapy and remained responsive to G-CSF after failing immunosuppressive therapy, suggesting defective hormone-mediated neutrophil survival rather than immune-mediated destruction. This observation led us to investigate a subset of chronic idiopathic neutropenia (CIN) for a previously unrecognized progesterone-responsive disorder. Although reproductive hormones have long been recognized to influence neutrophil biology, with cyclic variation across the menstrual cycle and physiologic neutrophilia during pregnancy accompanying sustained progesterone and estrogen exposure, these observations have never been systematically investigated in adults with CIN.

Methods and Results: To determine whether this phenotype extended beyond a single patient, we evaluated 238 consecutive adults referred for chronic neutropenia. Eighty-eight had large granular lymphocytic (LGL) leukemia-associated neutropenia, 63 had autoimmune neutropenia defined by anti-neutrophil antibodies, and 87 met criteria for idiopathic neutropenia. Extended blood-group phenotyping identified 12 patients with Duffy-null associated neutrophil counts yielding a final cohort of 75 adults with CIN following rigorous clonal and antigenic exclusion.

Within this idiopathic cohort, 54 of 75 patients (72%) were women (mean age 45±16 years). Importantly, although many presented beyond peak reproductive age, historical reproductive features revealed a consistent phenotype. Among women with documented menstrual histories, 50% reported irregular menses, exceeding the 15-20% population rate. Among those with documented pregnancies, 70% experienced transient normalization or marked improvement of neutrophil counts during gestation, with recurrence of neutropenia within six months postpartum, a natural experiment of sustained progesterone exposure. Several women also reported prior improvement with exogenous progestin therapy. No patients carried a diagnosis of endometriosis, consistent with the neutrophilic inflammatory phenotype typically associated with endometriosis rather than neutropenia. Together, these observations suggested that reproductive endocrine biology, rather than pregnancy itself, identifies a clinically recognizable subtype of CIN.

To investigate the molecular basis of this phenotype, we leveraged pregnancy as a physiologic model of sustained progesterone signaling. Bulk RNA sequencing of pregnancy-associated hematopoiesis (GSE235508, n=335) demonstrated coordinated upregulation of both the progesterone receptor (PGR; FDR=0.019, +1.77 log2FC) and the neutrophil pro-survival factor BCL2A1 (FDR<0.001, +1.00 log2FC). BCL2A1, a downstream effector of G-CSF/JAK2/STAT5 signaling, was the principal progesterone-responsive survival mediator. In published neutrophil-count GWAS data (Vuckovic et al., Cell 2020), the STAT5B locus was independently implicated, providing orthogonal support for this pathway. Mediation analysis resolved a coordinated PGR→TRIM28→BCL2A1 regulatory network in which progesterone relieved TRIM28-mediated repression (β=-0.120, P<0.0001) while directly activating BCL2A1 (direct β=+0.100, P=0.002; Sobel P=1.3×10?4), providing a mechanistic explanation for the pregnancy-associated remission observed clinically. Neutrophil-associated loci further converged with established polycystic ovary syndrome susceptibility genes (THADA, JAZF1, HMGA2), suggesting a shared inherited architecture linking reproductive endocrine regulation with neutrophil homeostasis.

Conclusions: These findings define a previously unrecognized progesterone-responsive endotype of CIN characterized by a consistent reproductive phenotype, including irregular menses, improvement with endogenous and exogenous progesterone exposure, preserved responsiveness to G-CSF, and a molecularly defined progesterone-BCL2A1 neutrophil survival axis. Rather than representing a heterogeneous diagnosis of exclusion, a subset of adult CIN appears to reflect defective progesterone-mediated neutrophil survival. This work establishes the first biologically defined endocrine endotype of adult CIN and identifies the progesterone-BCL2A1 pathway as a therapeutically actionable target for disease-directed intervention.

Mark David Orland, MD, PhD: No relevant conflicts of interest to declare.